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Bipolar Disorder (BD) is a chronic psychiatric illness that has no definitive cause nor 
cure. Symptoms of BD include elevated mood swings, alternating between anger and depression 
with anxiety. Heritability of BD is high and specific genetic markers of BD overlap with other 
neuropsychiatric conditions such as schizophrenia and major depression (Gordovez, F., & 
McMahon, F. J., 2020). Although researchers have previously used mice or postmortem human 
brain tissue to investigate the cause of BD, these models fail to take into account the effects of 
changes in brain structure due to medication or life stressors as well as changes at death. To 
address cellular changes, BD can be studied using human induced pluripotent stem cells or 
hiPSCs. HiPSCs are pluripotent, can form all cells of the body like human embryonic stem cells 
(hESCs), and provide a 2-D in vitro model for BD following differentiation of hiPSCs into 
neurons. Recent advances have considerably improved cultures to derive 3-D brain organoids. 
Brain organoids have the remarkable capability to self-organize without added signals to 
differentiate specific brain regions, creating a 3-D model of the developing human brain. In this 
manuscript we obtain adult skin fibroblasts from bipolar patients and cultured them into hiPSCs. 
Next, we differentiated them into brain organoids and observed morphological differences 
between control, bipolar cells containing a SNP associated with BD, and hiPSCs that underwent 
gene editing to correct the SNP (CRISPR corrected brain organoids). We then looked for any 
transcriptional abnormalities in expression of neural markers and BD susceptibility genes such as 
CACNA1C. Using immunohistochemistry, organoid sections were also stained for neuronal 
markers, to identify differences in protein expression between bipolar, control, and CRISPR 
corrected lines on days 30, 60, and 90 of in vitro development. We found that in bipolar cell 
3 
lines, VGLUT-1 expression levels were significantly lower compared to control and CRISPR 
corrected lines at day 60. PAX6 transcripts were elevated in BD CRISPR corrected day 30 
relative to BD day 30 samples which presumably produced expression of downstream targets 
marking glutamatergic and GABAergic neurons at day 60 as well. While these results provide 
useful information about the cellular mechanisms of BD, more remains to be done to discover 





















Bipolar Disorder (BD) is a chronic psychiatric illness that displays oscillations in mood 
from manic to depressive episodes. It has been estimated that approximately 45 million people 
worldwide suffer from BD (GBD 2017 Disease and Injury Incidence and Prevalence 
Collaborators, 2018). In addition, BD has been associated with other comorbidities such as 
cardiac abnormalities and diabetes, increasing the morbidity of this condition (Kim et. al, 2017). 
BD proves to be challenging as people may fail to distinguish manic or depressive symptoms as 
illness-related, leading to delayed diagnosis (Baldessarini RJ et. al, 2007). There is a small yet 
consistent genetic contribution to BD but despite this, little is known regarding the molecular 
pathology of BD (Mendlewicz, J., Rainer, J., 1977).  
Animal models such as mice are ideal for studying the basis of diseases such as 
Alzheimer’s, but not BD. This is because symptoms such as depression and mania used to 
diagnose BD in humans cannot necessarily be recapitulated and identified in murine models. 
This is a barrier to developing human-oriented therapeutic drugs with high efficacy. Although 
psychostimulants such as cocaine have been used to induce mania-like behavior in mice, experts 
have still been unable to create murine models that show spontaneous alternating episodes of 
manic and depressive-like behaviors (Nestler, E., Hyman, S., 2010).  
Noninvasive imaging and postmortem human brain studies have revealed 
neuroanatomical changes in the bipolar brain but these changes are not universal. Noninvasive 
human brain imaging does not provide an accurate depiction of molecular/cellular pathology to 
identify BD mechanisms and postmortem human brain tissue fails to highlight disease 
progression and treatment effects in BD patients (Wen, Z., et. al, 2016). In addition, since 
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postmortem human brain tissue is typically not amenable to tissue culture, the ability to derive 
stem cells from patients with BD provides an in vitro method to model the cellular mechanisms 
underlying it (Takahashi, K., et. al, 2007).  
 Human induced pluripotent stem cells (hiPSCs) are derived by reprogramming adult skin 
fibroblasts or other somatic cells via overexpression of the four “Yamanaka” factors (Oct3/4, 
Sox2, Klf4, and c-Myc) (Takahashi, K., et. al, 2007). High expression of these factors activate 
Nanog, a pluripotency gene that causes other genes involved in early human development to be 
activated, allowing researchers to model embryonic development in hiPSCs (Nakagawa, M., 
2008). HiPSCs have the ability to differentiate into all cell types in the body including neurons. 
These hiPSCs are similar to human embryonic stem cells (hESCs) in terms of morphology, gene 
expression, and proliferation, making them a great alternative to hESCs to mitigate any ethical 
concerns. The fact that adult somatic fibroblasts can be turned back into hiPSCs allows 
researchers to derive patient specific disease models. Furthermore, hiPSCs make genetic studies 
of neuropsychiatric disorders more feasible, since the unique genome of the donor is retained and 
one can study the progression of BD for example throughout differentiation (Christian K.M., et. 
al, 2012).  
By differentiating hiPSCs into neurons, scientists have discovered new data about BD. 
For example, 12-week bipolar neurons differentiated from hiPSCs when pretreated with Lithium, 
a drug commonly used to treat BD, showed decreased calcium transients and wave amplitudes 
similar to controls (Chen, H. M., et. al, 2014). Comparing BD versus control neurons, another 
study suggests that gene expression in bipolar neurons and neural progenitor cells (NPCs) 
derived from hiPSCs is altered in candidate genes involved in psychiatric disorders in 
comparison to controls. One gene called CACNA1C (O'Shea, K. S., & McInnis, M. G., 2016). 
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encodes an L-type, calcium alpha 1C subunit gene that according to several genome wide 
association studies (GWASs), has a single nucleotide polymorphism (SNP) at rs1006737 from G 
to A which is highly associated with BD (Sklar, P., et. al., 2008; Ferreira, M. A., et. al., 2008). 
Given the high degree of heritability of BD and GWASs performed, CACNA1C is one 
susceptibility gene that merits further research and is investigated in this study (Uemura, T., 
Green, M., & Warsh, J. J., 2016). 
Although hiPSC-derived neurons provide a better method for modeling development and 
the genetic underpinnings of BD than animal models or postmortem tissue, one limitation of in 
vitro neuronal cell culture is that neurons are grown in a 2-dimensional plane. Instead, brain 
organoids serve as a convincing alternative due to their three-dimensional nature and ability to 
self-organize, which is more representative of the human brain (See Figure 1).  
Whereas 2-D in vitro cell models are usually differentiated using protocols that form only 
single cell types such as astrocytes, brain organoids can self-organize and give rise to many cell 
types. Very similar to in vivo embryonic development, hiPSCs can independently form embryoid 
bodies that consist of 3 germ layers: endoderm, mesoderm, and ectoderm via a gastrulation-like 
process (McCauley, H. A., & Wells, J. M., 2017). By inhibiting the BMP4 and Nodal pathways with 
dual SMAD inhibitors for example, ectodermal tissue can be committed to a neural fate, which 
can give rise to many neural cell types such as astrocytes, neurons, etc. (Chavali, V.R.M., Haider, 
N., Rathi, S. et al., 2020). Independent organization within brain organoids proceeds much like the 
human brain via growth factors such as BDNF, creating new ways to alter cellular signaling 
pathways and derive patterned brain organoid regions (Farhadi, H. F., et. al., 2000). In the case of 
BD, brain organoids can provide a feasible model to identify potential genetic underpinnings, 
especially with susceptibility genes like CACNA1C. This can be done by creating isogenic iPSC 
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lines in which CRISPR-Cas9 gene editing is used to correct a suspected gene variant such as 
rs1006737 in CACNA1C and determining if this rescues the mutant phenotype (Amin, N. D., & 
Paşca, S. P., 2018).  
Derived ultimately from hiPSCs induced to form neuroectoderm, brain organoids were 
first used to model microcephaly, demonstrating that this in vitro method is capable of 
recapitulating human brain development and potentially other neuropsychiatric diseases as well 
(Lancaster, M. A., 2013). In the complex case of BD, brain organoids offer a model with enough 
regional diversity to allow investigations to be conducted on multiple cell types at once. Brain 
organoid culture, unlike neurons grown in 2-D, allows cells to be grown in suspension, thereby 
providing a more convincing model of the in vivo human brain. By creating this three 
dimensional and more mature cellular environment, accurate depictions of BD changes 
throughout regional development can be identified and used to then test therapeutic drugs 
specific to BD (Quadrato, G., Brown, J., & Arlotta, P. 2016). The human forebrain forms from 
an inner stem cell population that migrates to the pial surface. By examining gene/protein 
expression in the formed layers, it is possible to determine the cell composition of that region. 
Here we identify morphological differences and transcriptional alterations between hiPSC 
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Culture and generation of cerebral organoids from hiPSCs 
 
Skin biopsies were obtained from bipolar patients carrying the “AA” variant in the 
CACNA1C gene from “GG” control patients, expanded in vitro, and were subsequently 
reprogrammed to form hiPSC lines. 4 control (C5G, C8WW, C10V, C9G), 4 bipolar (BP17A, 
BP18A, BP19D, BP11E), and 3 CRISPR (BP17A CRISPR, BP18A CRISPR, BP19D CRISPR) 
corrected hiPSC cell lines were grown on 60mm TC dishes (Corning, Cat. No. 354004) coated 
with 0.083mg/mL of Matrigel (Corning, Cat. No. 356234) in DMEM (Gibco, Cat. No. 
11054020). hiPSCs were maintained in E8 medium (Stem Cell Technologies, Cat. No. 05991). 
Upon reaching 80% confluence, hiPSCs were washed once with Dulbecco’s phosphate buffered 
saline without calcium or magnesium (DPBS -/-) (Gibco, Cat. No. 14190136) and passaged 
using L7 (Lonza, Cat. No. 5013). To generate embryonic bodies, 80% confluent hiPSCs were 
washed with DBPS -/- and treated with Accutase (Millipore, Cat. No. SCR005) dissociation 
reagent for 90 seconds at 37°C. After 90 seconds, Accutase was removed, hiPSCs were triturated 
to make a single cell suspension using E8 media. hiPSCs were collected in a 15mL conical tube 
and centrifuged at 1000 rpm for 3 min at room temperature. The pellets of the hiPSCs were 
resuspended in E8 media supplemented with Y27632 (ROCK inhibitor, Tocris, Cat. No. 1254) to 
inhibit cell death and were plated in a 96-well U bottom plate (Costar, Cat. No 07-200-95) at 
20,000 cells per well to form embryoid bodies. 
After 48 hours, embryoid bodies were carefully transferred to 6 well ultra-low attachment 
plates (Costar, Cat. No. 3471) and media was changed to hiPSC media with 2ml per well for the 
next 4 days. hiPSC media consists of DMEM/F12 with HEPES (Gibco, Cat. No. 11330032), 
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KOSR (Gibco, Cat. No. 10828-028), MEM NEAA (Gibco, Cat. No. 11140-050), GlutaMAX 
(Gibco, Cat. No. 35050-061), 2-Mercaptoethanol [0.1mM] (Sigma-Aldrich, Cat. No. M3148), 
and FGF-2 [10ng/mL] (Peprotech, Cat. No. 100-18B-250UG).  
From day 6-25 hiPSC media was changed to neural induction medium (NIM) with 3ml 
per well to induce neuroectoderm formation. NIM media consists of DMEM/F12, KOSR, MEM 
NEAA, GlutaMAX, Penstrep (Gibco, Cat. No. 15140122), 2-Mercaptoethanol, Dorsomorphin 
inhibitor [5µM] (Cayman Chemical, Cat. No. 11967), and SB inhibitor [10µM] (Cayman 
Chemical, Cat. No. 13031). Dorsomorphin inhibitor and SB inhibitor are used to inhibit BMP 
and nodal signaling to promote forebrain neuroectoderm differentiation.  
Neuroectoderm typically forms after 5 days and after that neural spheroids become 
patterned forebrain organoids in a 6 well ULA plate with 4ml of NDM (neural differentiation 
medium). NDM consists of Neurobasal medium (Gibco, Cat. No. 21103-049), B27 (Gibco, Cat. 
No. 17504-044), GlutaMAX, Penstrep, EGF [20ng/mL] (Peprotech, Cat. No. AF100-15), FGF-2 
[20ng/mL], NT3 [20ng/mL] (Peprotech, Cat. No. 450-03-10UG), GDNF [20ng/mL] (Peprotech, 
Cat. No. 450-10-50UG) and BDNF [20ng/mL] (Peprotech, Cat. No. 450-02-50UG). Brain 
organoids were maintained with NDM media for long-term growth. Protocol was modified from 
Sloan, S.A., et. al, 2018. 
 
Organoid Imaging and Analysis: 
  
 On day 6, neural spheroids were imaged at 5x on a Leica DMi1 inverted microscope. 
Images were uploaded to ImageJ where each file was scaled, thresholded, and analyzed to obtain 
spheroid area in mm2. Any fused spheroids or those cut off from the images were not analyzed. 
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ImageJ “smooth” technique was used to mitigate debris from appearing in the threshold and 
being counted as an organoid. Average spheroid circularity was recorded for each cell line and 
subsequently an unpaired two-tailed t-test was performed using Graphpad Prism to identify any 
significant differences between pairs of control, bipolar, and CRISPR corrected spheroid cell 
lines. 
 
RNA Isolation, PCR, and Quantitative PCR: 
 
Day 30, 60, and 90 brain organoid samples for each cell line were collected and washed 
once with DPBS -/-. RNA was isolated using Qiagen RNeasy mini kit and RNase-Free DNase 
set (Qiagen, Cat. No. 74104). RNA concentrations were measured using a Nanodrop machine 
(Thermo Scientific, Cat. No. 2000-C) and stored at -80°C until further use. Complimentary DNA 
was prepared by reverse transcription using the SuperScript III First-Strand Synthesis SuperMix 
for RT-qPCR (Thermo Fisher, Cat. No. 18080051). qPCR was conducted in a 96 well plate 
(Applied Biosystems, Cat. No. 4346906) using Applied Biosystems QuantStudio 3 (Cat. No. 
A28571) where all samples were run in triplicates. Target and housekeeping genes used in this 









Table 1: Primers for target genes for qPCR 
Gene Description Forward Primer  Reverse Primer  Cat. No. 
Forward/Rever
se 
CACNA1C L-type, calcium 


















































All qPCR samples were ran for 40 cycles of 95°C at 3 minutes and 30 seconds, 60°C for 
30 seconds, 72°C for 35 seconds followed by a melt curve of 95°C for 15 seconds, 60°C for 1 
minute, and 95°C for 15 seconds. Gene expression analysis was normalized to the GAPDH 
housekeeping gene and expressed as fold change compared to controls day 30, 60, and 90. To 
analyze for significance, an unpaired Welch corrected two-tailed t-test was performed on 







 Organoids were washed in Dulbecco’s phosphate buffered saline with calcium and 
magnesium (DPBS +/+) to preserve the cytoskeleton (Thermofisher, Cat. No. 14040141), fixed 
with 4% PFA (Electron Microscopy Sciences, Cat. No. 15700) for 10 minutes and stored at 4°C 
in DPBS+/+. Fixed samples were flash frozen in O.C.T. embedding compound (Fisher Scientific, 
Cat. No. 4585) in tissue pathology disposable base molds (Thermo Scientific, Cat. No. 41-741). 
10 and 20 µm tissue sections were cut using a microtome (Thermo Scientific, Cat. No. 





Tissue sections were brought to room temperature and washed with DPBS +/+ to remove excess 
O.C.T.. Sections were permeabilized with 0.1% Triton (Sigma-Aldrich, Cat. No. T9284-500ML) 
and 0.1% Sodium Citrate (CalBioChem, Cat. No. 567446) in DPBS +/+. Samples were then 
washed twice with DPBS +/+ and blocked with 10% Normal Donkey Serum (Jackson 
ImmunoResearch, Cat. No. 017-000-121) containing 10% Triton and 10% Sodium Azide 
(Sigma-Aldrich, Cat. No. S2002-5G) in DPBS +/+. After blocking, samples were stained for the 









Description Dilution Company/Cat. No. 
Tubb3-Ck                                                                                                                   Tubulin present in neuron
axons 
1:500 Abcam, Cat. No. AB107216 
Pax6- Ms       Neural progenitor cell marker 1:500     Millipore, Cat. No. MAB5552 
Nkx2.1-Rb        Transcription factor involved 
with early neuron migration 
1:250          Abcam, Cat. No. AB76013 
Vglut-1-Gp                                                                                Glutamatergic marker 1:500       Millipore, Cat. No. AB5905 
Neun-Ms         Neuronal nuclei marker 1:100      Millipore, Cat. No. MAB377 
Gad67-Rb         GABA marker 1:500              Abcam, Cat. No. AB49832 
PV-Ms                                                                                           Specialized GABA marker 1:500     Millipore, Cat. No. MAB1572 
GFAP-Gt        Astrocyte marker 1:100      Santa Cruz, Cat. No. SC-6170 
Syn1-Rb     Synapse marker 1:200           Cell Signaling, Cat. No. 5297 
 
 
The following day tissue samples were washed twice with DPBS +/+  and stained in the dark for 







Table 3: Secondary Antibodies used for Immunostaining 
Secondary Antibody Dilution Company/Cat. No. 
 Green 488 Dk anti Ck 
(Tubb3)                                                                          
1:500                Jackson Immunoresearch, Cat. No. 703545155 
Orange 555 Dk anti Ms 
(Pax6)     
1:500     Alexa Fluor, Cat. No. A31570 
Red 594 Dk anti Rb (Nkx2.1)  1:500          Jackson Immunoresearch, Cat. No. 711585152 
Green 488 Dk anti Gp 
(Vglut-1)                                                        
1:500       Jackson Immunoresearch, Cat. No. 706545148 
Orange 555 Dk anti Ms 
(Neun) 
1:500      Alexa Fluor, Cat. No. A31570 
Red 594 Dk anti Rb (Gad67)  1:500              Jackson Immunoresearch, Cat. No. 711585152 
Orange 555 Dk anti Ms (PV)                                       1:500 Alexa Fluor, Cat. No. A31570 
Green 488 Dk anti Gt (GFAP)    1:500      Santa Cruz, Cat. No. sc-2020 
Purple 647 Dk anti Rb (Syn1) 1:500           Jackson Immunoresearch, Cat. No. 711605152 
 
 
Samples were once again washed with DPBS +/+ and stained with a 1:1000 dilution of 
Hoechst (Thermo Fisher, Cat. No. 33258) for 5 minutes to stain DNA. Samples were then 
washed with DPBS +/+ and 1mm thick coverslips (Electron Microscopy Sciences, Cat. No. 
71887-03) were applied with Prolong Gold antifade mounting media (Thermo Fisher, Cat. No. 
P36930). Slides were left to dry and stored at room temperature in the dark. Samples were 
examined using DAPI, GFP, Cy3, and Cy5 filters and were imaged on a Leica DMi8 fluorescent 
microscope at 5x and 10x. Single channel images were merged with 497.5um and 248.7um for 





Discrepancies in circularity among control, bipolar, and CRISPR corrected lines suggest 
differences in cell division and differentiation: 
 
 
To determine if control, BP, and CRISPR cell lines grew similarly in the same culture 
conditions (see Methods), cerebral spheroids were imaged on day 6 prior to neural induction 
(Figure 2). To analyze morphological differences, circularity was measured for n = 100 
spheroids per cell line and results were graphed and analyzed for significance with a two-tailed 
unpaired t-test (Figure 3). BP cell lines showed a significant decrease in circularity compared to 
control and CRISPR lines (p < 0.0001 and p < 0.001 respectively) which appear to be more 
radially organized. Circularity between controls and CRISPR lines however exhibited no 
significant differences in circularity. These results suggest that BP cell lines may have undergone 
less organized cellular division and differentiation than control and CRISPR lines by day 6. Also, 
differences in circularity between control and CRISPR groups were not significant, consistent 
with our expectations that control groups should have similar circularity compared to CRISPR 
groups. Therefore, other measurements of proliferation and differentiation may be useful such as 









Figure 2: 5x images of day 6 cerebral spheroids in control (C5G), bipolar (BP19D), and 
CRISPR corrected (BP19D CRISPR) cell lines illustrating morphological differences between 



















Figure 3: Distribution and statistical analysis of a measure of circularity between various groups. 






Comparison of fold change in neural gene expression shows increasing levels of PAX6, 
VGLUT-1, and GAD67 at various stages of brain organoid development: 
 
 
 To investigate transcriptional alterations throughout early brain organoid development 
among control, BP, and CRISPR lines, qPCR was performed with C5G, BP19D, and BP19D 
CRISPR on day 30, 60, and 90 samples for 5 transcripts (see Table 1). Using GAPDH as a 
housekeeping gene, a global control day 30 normalized fold change curve was generated for 
PAX6, GFAP, VGLUT-1, GAD67, and CACNA1C (Figure 4). Overall, these preliminary results 








Normalized fold changes on day 30 show an approximate 5-fold and 26-fold increase in 
expression of the early neural marker PAX6 in BP19D and BP19D CRISPR respectively relative 
to C5G (Figure 5A). Fold change increases in GFAP, VGLUT-1, GAD67, and CACNA1C were 
similar across BP and CRISPR corrected groups as well. These two observations are consistent 
with each other since PAX6 is a neural progenitor cell (NPC) marker and low expression of 
neuron markers such as VGLUT-1 (glutamatergic neuron marker) and GAD67 (GABA neuron 
marker) showed that these neurons have not yet matured in day 30 samples.  
Examining normalized fold changes on day 60, expression of PAX6 decreases and 
VGLUT-1 fold change levels become significantly higher (relative to BP19D for C5G and 
BP19D CRISPR) (Figure 5B). GAD67 fold change levels also rise compared to day 30 but are 
expressed at varying levels across all three cell lines at day 60. These results suggest an increase 
in the presence of glutamatergic neurons at day 60 in BP19D CRISPR relative to C5G. This is 
maybe due to the differentiation of NPCs that were previously enriched at day 30. For fold 
changes normalized and grouped by day 90, BP19D CRISPR still showed higher VGLUT-1 
expression relative to C5G. In addition, fold change levels of all other markers do not show 
much change in relation to C5G at day 90 (Figure 5C).  
When analyzing fold changes in target genes on days 30, 60, and 90 normalized to day 30 
samples of each cell line, PAX6, VGLUT-1, and GFAP all consistently increased as brain 
organoids matured from day 30 to day 90 (Figures 6-8). GAD67 fold change levels are 
significantly higher in C5G and BP19D than VGLUT-1 suggesting a higher presence of GABA 
neurons than glutamatergic (Figure 6B/D and 7B/D). It is worth noting that GAD67 levels 
decreased from day 60 to day 90 in BP19D CRISPR cell lines possibly because as neurons 
expressing GABA mature, they start to down regulate the synthesis of GAD67 (Figure 8D). 
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GFAP is an astrocyte marker that usually does not appear until day 120, yet it showed in day 90, 
indicating early differentiation of astrocytes (Figure 6C, 7C, 8C). GFAP levels at day 90 were 
considerably lower in BP19D and BP19D CRISPR compared to C5G. Also, changes in  
CACNA1C levels appear to be highest during day 90 for each line however the highest fold 























































































Figure 5: Mean fold change in neural gene expression in lines C5G, BP19D, and BP19D 







































































Figure 6: Mean fold change in neural gene expression on day 30, 60, 90 in the C5G line. * = 






Figure 7: Mean fold change in neural gene expression on day 30, 60, 90 in the BP19D line. * = 






Figure 8: Mean fold change in neural gene expression on day 30, 60, 90 in the BP19D CRISPR 
line. * = p<0.05, ** = p<0.01, *** = p<0.001 , **** = p<0.0001 
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Immunohistochemical localization of neural markers are consistent with qPCR results. 
Markers not examined by qPCR merit further research: 
 
 
 To evaluate protein expression levels within the brain organoid samples, tissue sections 
were cut and stained for 9 markers (see Table 2) via immunohistochemistry (IHC). For all day 30 
samples, Tubb3 was clearly expressed (Figure 9A and 10A). Tubb3 is a microtubule marker 
present in neurons. Pax6 was also expressed in all day 30 samples which is concordant with 
qPCR results (Figure 9A and 10A). In addition, Vglut-1, Gad67, Neun (neuronal nuclei marker), 
and Nkx2.1 (neuronal migration TF marker) were not detectable except in BP19D CRISPR day 
30 samples (Figure 9B and 10B). Furthermore, Syn-1 (neuron synapse marker) was present and 
Parvalbumin (PV) was absent in all day 30 samples (Figure 9C and 10C). This is expected 
because PV (specialized GABA neuron marker) usually is expressed later in development 
(Sloan, S.A., et. al., 2018). GFAP, although usually expressed by day 120, is present in C5G and 
BP19D CRISPR on day 30 although this is likely due to early differentiation (Figure 9A/C and 





































 Day 60 tissue samples were also stained for the same markers and as expected, Tubb3 
was present in all day 60 samples (Figure 11A and 12A). In addition, neuronal markers such as 
Nkx2.1, Vglut-1, Neun, and Gad67 started to become visible too, validating the qPCR results 
done for VGLUT-1 and GAD67 (Figure 11B and 12B). Syn-1 was present in all day 60 samples 
and PV was not. GFAP was detected in BP19D Day 60 only which also suggests early 

































































 Tubb3 was detected in all day 90 samples along with Syn-1 (Figure 13C and 14C). GFAP 
was also present at day 90 in C5G and BP19D CRISPR, suggesting early differentiation in these 
cell lines. Nkx2.1 was present in C5G and is faintly expressed elsewhere in BP19D and BP19D 
CRISPR (Figure 13A and 14A). Gad67 was found in C5G and BP19D CRISPR while Neun and 

































































 From qPCR and IHC data, my results suggest that throughout days 30-90 of 
development, brain organoids gradually give rise to mature neurons and astrocytes. As PAX6 
expression increased, VGLUT-1 and GAD67 fold changes gradually increased, illustrating the 
differentiation of NPCs into mature neurons. This is especially true for BP19D CRISPR which 
expressed high levels of PAX6 leading to increased maturation of glutamatergic neurons relative 
to C5G and BP19D. In addition, GFAP was also expressed at the highest level on day 90 for 
C5G, BP19D, and BP19D CRISPR. Although this astrocyte marker has been reported to be 
present in day 120 samples, GFAP was present at day 90, suggesting that early differentiation of 
these cells occurred. Furthermore, CACNA1C fold change levels were highest in BP19D on day 
90, consistent with CACNA1C levels being higher in BP patients than in control and CRISPR 
corrected cell lines.  
 Overall, brain organoids are useful models for studying later stages of forebrain 
development. Although gene expression assays such as qPCR can be performed in 2D neuronal 
cultures, 3D organoids allow for identification of later forming glia such as astrocytes. In this 
capacity, human brain development can be best modeled in brain organoids given their ability to 
self-organize and give rise to multiple neural lineages. There are also limitations in protein 
localization for 2D neurons in vitro as well. As evident through immunostaining, brain organoids 
at later stages of development express different proteins compared to early stages. For example, 
Vglut-1 and Gad67 were present in day 60 samples, unlike day 30 and GFAP was present in day 
90 samples unlike day 30. Also, throughout the developmental stages, protein markers can be 
detected in different regions of tissue such as the periphery which is where many of these 
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proteins are expressed. This is because different neural cell types are formed in unique cortical 
layers of organoid tissue. In vivo, NPCs are found in regions such as the ventricular zone (VZ) 
and subventricular zone (SVZ) (Figure 15). As brain organoids mature further, deep/upper 
neuronal markers such as TBR1, SATB2, and CTIP2 start to be detected, forming the cortical 
plate (CP). Eventually, astrocytes develop and support neuron cell types in the CP. The 
organization of these cell types in developing brain organoids are similar to that of the fetal 
human brain, making it feasible to use organoids to model the cellular composition of brains 
from patients with BD. 
 
 
Figure 15: Schematic representation of brain organoid cortical layer development in vitro (Di 
Lullo, E., & Kriegstein, A. R., 2017). 
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 In addition, the use of CRISPR corrected organoids allows us to better investigate the 
role of CACNA1C (SNP rs1006737) in individuals with BD. Since control and BP cell lines 
contain the “GG” and “AA” CACNA1C variant respectively, by utilizing BP CRISPR cell lines 
to correct the “AA” variant back to “GG”,  we can potentially determine if BP CRISPR corrected 
lines are different compared to BP cell lines. More specifically, BP CRISPR corrected cell lines 
can elucidate whether the correction of the CACNA1C SNP results in transcriptional alterations 
or protein expression changes in comparison to BP cell lines. This is because we expect BP 
CRISPR lines to be similar to controls, which was true when we analyzed spherical organization 
with circularity. 
Despite having shown significant differences in gene/protein expression in control, BP, 
and BP CRISPR corrected brain organoids with development, there is much to be done in order 
to investigate the underlying cellular mechanisms underlying behaviors of patients with BD. 
Since only one control, BP, and BP CRISPR corrected line was used so far, additional lines (3 
control, 3 BP, and 3 BP CRISPR corrected) are being analyzed for a larger sample to examine 
for variations in gene or protein expression.  
 Additionally, more genes should be examined to identify the patterns underlying BD. 
Although a few genes were examined in qPCR, more genes need to be measured. For these 
reasons, transcriptome analysis via bulk RNA sequencing of control, BP, and CRISPR corrected 
cell lines is currently being carried in 3 lines each, to screen for approximately 22,000 genes in 
the sequencing core. From there, any additional genes of interest will be validated with qPCR 
and IHC. 
 Furthermore, while IHC data has allowed us to validate qPCR results of additional genes 
such as Syn-1, Nkx2.1 and PV should be examined. However, this work only provides a 
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snapshot of protein expression in one organoid section. Instead, additional IHC of serial sections 
should be performed to better understand specifically where certain protein markers localize. By 
staining multiple slices of a particular organoid, 3D computer generated models can be 
developed to characterize protein localization overall. Furthermore, since brain organoid sections 
were cut at 10µm and 20µm, perhaps higher resolution imaging techniques such as confocal 
microscopy should be used to effectively image organoids that have different depths.  
 Long term organoid culture is needed to understand gene and protein expression levels 
past day 90. As previously mentioned, CACNA1C and GAD67 level fold changes normalized to 
BP19D day 30 were highest in the BP19D day 90 sample along with GFAP in all day 90 
samples. By examining brain organoids at even later stages of development such as day 200 or 8 
months, perhaps additional changes in gene and protein expression could be observed for 
example, the appearance of other cell markers such as the specialized GABA gene Parvalbumin. 
8-month unpatterned organoids samples have been harvested and collected but not yet analyzed.  
 Also, in addition to patterning forebrain organoids, fused assembloids may merit further 
research. Having already cultured dorsal forebrain organoids, fusing ventral forebrain spheroids 
with dorsal may provide more insight into BD. By fusing the dorsal and ventral forebrain 
spheroids together, GABAergic neurons from the ventral forebrain can migrate to the dorsal side 
and integrate to network with cortical glutamatergic neurons (Sloan, S.A., et. al., 2018). By 
generating these assembloids, neural circuit formation could potentially be characterized from 
control, BP, and BP CRISPR corrected cell lines. In addition, electrophysiology experiments 
such as patch clamp could be performed on region specific cells of assembloids to better 
ascertain neuron specific interactions in 3D cultures (although this fails to capture global analysis 
(Passaro, A. P., & Stice, S. L., 2021)). Live calcium imaging can also be used to analyze network 
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activity although in small specific regions of interest (ROI) only. Therefore, recent advancements 
in microelectrode arrays and optogenetics may compensate for limitations in patch clamp and 
calcium imaging in brain organoids, since spatial and temporal resolutions are maintained. While 
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